Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
Clinical trial NCT03709953 · UNKNOWN
Trial details
- NCT number
- NCT03709953
- Sponsor
- Guangzhou Institute of Respiratory Disease
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-19
- Primary completion
- 2021-03-31
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.